SMT202500413T1 - Mavacamten per l’uso nel trattamento di cardiomiopatia ipertrofica - Google Patents

Mavacamten per l’uso nel trattamento di cardiomiopatia ipertrofica

Info

Publication number
SMT202500413T1
SMT202500413T1 SM20250413T SMT202500413T SMT202500413T1 SM T202500413 T1 SMT202500413 T1 SM T202500413T1 SM 20250413 T SM20250413 T SM 20250413T SM T202500413 T SMT202500413 T SM T202500413T SM T202500413 T1 SMT202500413 T1 SM T202500413T1
Authority
SM
San Marino
Prior art keywords
mavacamten
treatment
hypertrophic cardiomyopathy
hypertrophic
cardiomyopathy
Prior art date
Application number
SM20250413T
Other languages
English (en)
Italian (it)
Inventor
Marc Evanchik
Marc J Semigran
June H Lee
Joseph Lambing
Eric Green
Timothy Carlson
David Zhang
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of SMT202500413T1 publication Critical patent/SMT202500413T1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
SM20250413T 2017-08-04 2018-08-03 Mavacamten per l’uso nel trattamento di cardiomiopatia ipertrofica SMT202500413T1 (it)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762541591P 2017-08-04 2017-08-04
US201762584537P 2017-11-10 2017-11-10
US201862639922P 2018-03-07 2018-03-07
US201862671585P 2018-05-15 2018-05-15
PCT/US2018/045180 WO2019028360A1 (en) 2017-08-04 2018-08-03 MAVACAMTEN FOR USE IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
EP18759209.2A EP3661514B1 (en) 2017-08-04 2018-08-03 Mavacamten for use in the treatment of hypertrophic cardiomyopathy

Publications (1)

Publication Number Publication Date
SMT202500413T1 true SMT202500413T1 (it) 2025-11-10

Family

ID=63350605

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20250413T SMT202500413T1 (it) 2017-08-04 2018-08-03 Mavacamten per l’uso nel trattamento di cardiomiopatia ipertrofica

Country Status (19)

Country Link
US (5) US20200054636A1 (enExample)
EP (2) EP4659806A2 (enExample)
JP (3) JP2020529996A (enExample)
KR (2) KR20200035973A (enExample)
CN (2) CN111182901A (enExample)
AU (2) AU2018311974B2 (enExample)
CA (1) CA3071948A1 (enExample)
DK (1) DK3661514T3 (enExample)
FI (1) FI3661514T3 (enExample)
IL (2) IL322175A (enExample)
LT (1) LT3661514T (enExample)
MA (1) MA49760A (enExample)
MX (3) MX2020001406A (enExample)
MY (1) MY208231A (enExample)
RU (1) RU2020109345A (enExample)
SG (2) SG10202112960QA (enExample)
SM (1) SMT202500413T1 (enExample)
UY (1) UY37834A (enExample)
WO (1) WO2019028360A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117924208A (zh) 2018-01-19 2024-04-26 赛特凯恩蒂克公司 作为心肌节抑制剂的二氢苯并呋喃和茚类似物
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス， インコーポレイテッド 心臓サルコメア阻害剤
WO2020257609A1 (en) * 2019-06-21 2020-12-24 MyoKardia, Inc. Diagnostics and treatments for cardiac disease
CN110698415B (zh) * 2019-10-21 2023-05-09 上海先行医药开发有限公司 一种肌球蛋白抑制剂及其制备方法和用途
TW202134259A (zh) * 2019-11-10 2021-09-16 美商邁奧卡迪亞公司 用肌凝蛋白調節劑之治療方法
SI4097091T1 (sl) * 2020-01-28 2025-05-30 Assia Chemical Industries Ltd. Trdne oblike mavacamtena in postopek za njihovo pripravo
IL300775A (en) * 2020-08-28 2023-04-01 Myokardia Inc Treatment methods with myosin modulator
JP2023550444A (ja) 2020-11-20 2023-12-01 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 トリアジンジオン系誘導体、その調製方法及びその医薬的応用
MX2023008810A (es) * 2021-02-01 2023-08-04 Dr Reddys Laboratories Ltd Proceso de preparacion de mavacamten y formas en estado solido del mismo.
WO2022187501A1 (en) 2021-03-04 2022-09-09 Cytokinetics, Inc. Cardiac sarcomere inhibitors
CN112939876A (zh) * 2021-03-10 2021-06-11 杭州科巢生物科技有限公司 Mavacamten的晶型I及其制备方法
WO2022189599A1 (en) 2021-03-12 2022-09-15 Sandoz Ag Crystalline forms of mavacamten for the treatment of hcm
KR20240047359A (ko) 2021-07-16 2024-04-12 싸이토키네틱스, 인코포레이티드 비대성 심근병증을 치료하는 방법
US20240389972A1 (en) * 2021-09-24 2024-11-28 Koninklijke Philips N.V. METHODS AND SYSTEMS FOR GENERATING LIKELIHOOD OF HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
WO2024097284A1 (en) * 2022-11-02 2024-05-10 MyoKardia, Inc. Mavacamten and derivatives thereof for use in treating atrial dysfunction
WO2024206339A1 (en) 2023-03-27 2024-10-03 Edgewise Therapeutics, Inc. Quinolinone amide compounds and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202000071T1 (it) * 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache

Also Published As

Publication number Publication date
EP3661514B1 (en) 2025-09-17
AU2024203872A1 (en) 2024-06-27
LT3661514T (lt) 2025-11-10
TW201916882A (zh) 2019-05-01
US20220226324A1 (en) 2022-07-21
CN111182901A (zh) 2020-05-19
CA3071948A1 (en) 2019-02-07
IL272300B1 (en) 2025-08-01
JP2023065372A (ja) 2023-05-12
IL272300B2 (en) 2025-12-01
WO2019028360A1 (en) 2019-02-07
SG11202000549TA (en) 2020-02-27
EP4659806A2 (en) 2025-12-10
IL272300A (en) 2020-03-31
US20240423981A1 (en) 2024-12-26
FI3661514T3 (fi) 2025-12-12
UY37834A (es) 2019-02-28
US20220313695A1 (en) 2022-10-06
AU2018311974A1 (en) 2020-02-06
MA49760A (fr) 2020-06-10
US20200054636A1 (en) 2020-02-20
CN118593507A (zh) 2024-09-06
IL322175A (en) 2025-09-01
JP2025020292A (ja) 2025-02-12
RU2020109345A (ru) 2021-09-06
JP2020529996A (ja) 2020-10-15
MX2020001406A (es) 2020-03-09
MX2024008096A (es) 2024-07-15
EP3661514A1 (en) 2020-06-10
US20250213565A1 (en) 2025-07-03
AU2018311974B2 (en) 2024-03-07
MY208231A (en) 2025-04-25
SG10202112960QA (en) 2021-12-30
KR20200035973A (ko) 2020-04-06
DK3661514T3 (da) 2025-12-15
MX2024000348A (es) 2024-01-26
KR20250116181A (ko) 2025-07-31

Similar Documents

Publication Publication Date Title
IL272300B2 (en) Mebactam for use in the treatment of myocardial hypertrophy
IL275482A (en) Asketamine for the treatment of depression
GB201813876D0 (en) Treatment
LT4101454T (lt) Kompozicijos, skirtos naudoti hipertenzijos gydymui
SI3331610T1 (sl) Sredstva za uporabo pri zdravljenju gliomov
IL289371A (en) Methylthioninium for use in the treatment of synaptopathies
GB201800546D0 (en) Treatment
IL274363A (en) Use of a specific siRNA against protein S for the treatment of hemophilia
IL272658A (en) surface treatment
PL3448340T3 (pl) Pomocniczy element aplikacyjny do opatrywania ran
SMT202200221T1 (it) Medicinale per l'uso nel trattamento della gotta
ZA202006886B (en) R-fadrozole for use in the treatment of aldostonerism
IL269121A (en) Usl-311 for use in the treatment of cancer
LT3548006T (lt) Kompozicija, skirta žarnyno pakitimams gydyti
IL286533A (en) Compounds for use in the treatment of adcy5-related dyskinesia
SI3303486T1 (sl) Sestavek za površinsko obdelavo
GB201513543D0 (en) Compositions for use in the treatment of diabetes
ZA201801788B (en) Lysobactin for use in the treatment of bovine mastitis
GB201718985D0 (en) Treatment
HK40026724A (en) Mavacamten for use in the treatment of hypertrophic cardiomyopathy
GB201814905D0 (en) Treatment
GB201713650D0 (en) Treatment
GB201706955D0 (en) Treatment